570 related articles for article (PubMed ID: 24929235)
21. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
[TBL] [Abstract][Full Text] [Related]
23. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
Berg T; Zoulim F; Moeller B; Trinh H; Marcellin P; Chan S; Kitrinos KM; Dinh P; Flaherty JF; McHutchison JG; Manns M
J Hepatol; 2014 Apr; 60(4):715-22. PubMed ID: 24295873
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
32. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
[TBL] [Abstract][Full Text] [Related]
33. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
34. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
Seo SY; Kim IH; Sohn JY; Lee S; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG
Intervirology; 2014; 57(1):8-16. PubMed ID: 23988634
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
38. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
39. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
[TBL] [Abstract][Full Text] [Related]
40. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
